Mavenir Enables Faster 5G Service Creation with its BSS Digital Enablement Platform

21.7.2021 16:00:00 EEST | Business Wire | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud infrastructure and transforms the way the world connects, today announced its Business Support System (BSS) solution called Mavenir Digital Enablement (MDE) platform. The MDE Platform enables Communications Service Providers (CSPs) to quickly and easily build new digital offerings through a simplified graphical service experience creator. MDE can be deployed either as a standalone BSS or as an overlay on the CSP’s legacy BSS.

This solution uses a proven Microservices, API-first, Cloud-Native, Headless (MACH) architecture that is aligned with TM Forum’s Open Digital Architecture (ODA) and OpenAPIs. Its low/no-code UI enables agile experience creation. With a unified product catalog, MDE lets CSPs easily develop and deploy new services, speeding both time to market and time to revenue. The solution also provides tools for consolidation and transformation of network usage and non-usage data, which generates insightful information to help deliver hyper-personalized services and offerings through an omnichannel experience.

Mavenir’s unique technology enables a “composable” BSS architecture so CSPs can design their own BSS solution by assembling the right mix of microservices from the MDE library. It is designed to help CSPs innovate fearlessly without being restricted by the inflexibility of legacy BSS or IT systems. It also enables them to leverage their existing BSS/IT infrastructure by deploying the MDE Marketplace as an overlay solution. Use cases include:

Delivering greenfield MNO services
Enabling a digital marketplace for bundling CSP services with partner services to generate new revenue streams
Introducing a sub-brand in response to digital attacker brands or to address a niche segment of the market
Launching a new MVNO service by utilizing the MDE BSS as a Mobile Virtual Network Enabler (MVNE)

The MDE BSS platform can quickly and easily be deployed as an adjunct solution to launch new business services such as:

5G FWA/eMBB/AR/VR services
IoT services for B2C/B2B/B2B2X customers
Connectivity bundles for B2B customers
Unified communication (UCC) and contact center for B2B customers
Rich Business Messaging using RCS for B2B customers

“Mavenir’s MDE platform enables CSPs to deliver the promise of 5G and speed up the return on their 5G investments by eliminating perpetually slow processes and the barriers of cost and time from legacy BSS,” said BG Kumar, President Communications Services at Mavenir. “Through its open APIs, MDE easily integrates with existing IT or BSS systems and can run as an overlay solution, giving CSPs the option to escape existing vendor lock-in and freedom from development limitations on legacy IT systems.”

The solution is currently deployed with various CSPs in APAC, Europe, and the Americas.

Supporting documents:

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.

www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005238/en/

Contact information

Maryvonne Tubb
Mavenir
PR@mavenir.com

Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com

Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com

About Business Wire

Business Wire

http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom